Comparing Peptide Protocols: GH Stacks and Recovery Stacks

Why protocols get compared at all

Most people who use peptides for training goals combine two or more compounds, and forum guides argue about which combinations work best. This page compares the protocols that come up most often: growth hormone (GH) stacks built from a GHRH analog plus a GHRP, the long-acting CJC-1295 with DAC, and the BPC-157 plus TB-500 "recovery stack".

One caveat applies throughout. Nearly all of the human research on these compounds measured hormone levels, not muscle, fat loss or healing. When a guide calls one protocol "more effective", it usually means it raised GH more in a short lab study. As of October 2026, no controlled trial has tested whether any of these stacks changes results for lifters.

Growth hormone protocols: pulses vs. long-acting analogs

The body releases GH in pulses, mostly during sleep. GHRH (growth hormone releasing hormone) triggers release through its own pituitary receptor, while ghrelin and the synthetic GHRPs act on the ghrelin receptor (GHSR-1a). Somatostatin works as the brake.

The older approach: a GHRP on its own

Early protocols used GHRP-6 or GHRP-2 by itself. In a 1990 study of 18 healthy men, IV GHRP-6 raised peak GH from about 1 mcg/L on placebo to about 69 mcg/L at the top dose of 1 mcg/kg. At that dose, prolactin and cortisol also roughly doubled; lower doses didn't move them.

That spillover is the main reason community guides now treat GHRP monotherapy as dated. GHRP-6 also has a reputation for intense hunger, which fits its action on the ghrelin receptor. Users commonly describe hunger within 15-30 minutes of a dose, though we found no trial that measured appetite. Some lifters on a bulk welcome it; people who are cutting usually avoid GHRP-6.

GHRH plus GHRP

The most popular stack pairs a short-acting GHRH analog, usually Mod GRF 1-29 (CJC-1295 without DAC), with ipamorelin. The idea has human support: in the same 1990 study, low doses of GHRP-6 given with GHRH released more GH than the two would have added up to separately, which the authors read as two independent pathways.

Ipamorelin is usually picked for its selectivity. In a 1998 Novo Nordisk study in pigs, it released GH about as well as GHRP-6 but didn't raise ACTH or cortisol, even at more than 200 times the dose needed for GH release. GHRP-6 and GHRP-2 did raise cortisol in the same experiments. That's animal data. Ipamorelin's one efficacy trial, a Phase 2 study in 117 adults after abdominal surgery, missed its primary endpoint (median time to a first tolerated meal was 25.3 hours vs. 32.6 hours on placebo, not significant), according to FDA's 2024 review.

So GHRH-plus-GHRP synergy has been shown for GH release after single IV doses. We found no controlled human trial of the Mod GRF 1-29 plus ipamorelin pair itself, and none that measured muscle or fat. The stack's popularity rests on mechanism and user reports.

CJC-1295 with DAC and the "GH bleed" claim

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analog built to bind albumin in the blood. In 2006 studies in healthy adults, its half-life was 5.8-8.1 days. A single injection raised mean GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9-11 days.

Community guides, including an earlier version of this page, say the DAC form replaces natural pulses with a constant "GH bleed". The one study that checked found otherwise. In healthy men aged 20-40 given a single 60 or 90 mcg/kg dose, overnight sampling a week later showed GH pulses of unchanged frequency and size. What rose was the level between pulses: trough GH about 7.5-fold, mean GH 46% and IGF-1 45%. Pulses sitting on a raised floor is the more accurate picture.

Whether that raised floor helps or hurts training goals is untested. Users of both the DAC and no-DAC forms report water retention and numb or tingling hands. In the 2006 trials, injection-site reactions and flushing were common, and FDA's safety listing for CJC-1295 cites increased heart rate and systemic vasodilatory reactions. Nobody has compared side-effect rates for DAC and short-acting stacks head-to-head.

Recovery protocols: BPC-157 and TB-500

Vendors and forum guides describe BPC-157 and TB-500 as synergistic, with BPC-157 working at the injury and TB-500 working across the body. That division of labor is a community model that hasn't been tested.

BPC-157's evidence comes almost entirely from animals. In a 2003 rat study, daily intraperitoneal BPC-157 improved the strength and structure of healing after the Achilles tendon was cut. A 2025 systematic review found 36 relevant studies, 35 of them preclinical. The one human study was a retrospective series in which 7 of 12 people with chronic knee pain reported relief lasting over six months after a knee injection, and the review found no clinical safety data. Rodent work links BPC-157 to angiogenesis, which is where the local-repair story comes from. On the site's evidence scale, BPC-157 rates as emerging.

TB-500 is often sold as "thymosin beta-4", which isn't quite accurate. Anti-doping chemists identified it as Ac-LKKTETQ, a seven-amino-acid fragment (residues 17-23) of the 43-amino-acid protein. Most repair research, and the few human trials, used the full protein. As of October 2026, FDA says it has no human exposure data for the fragment, and TB-500 rates as preliminary on the site's scale.

User reports on the stack are mixed. Some describe clear improvement in a stubborn tendon within weeks; many report no change after 3-6 weeks. Product quality is one likely reason, since gray-market vials vary and some users can't tell whether their "TB-500" is the fragment or the full protein. Another is that no controlled trial has studied the injuries users are treating. Our collection of user experiences and case studies shows how wide the spread is.

How users match protocols to goals

None of the figures below comes from a trial of the stated goal. They're what community guides and users describe, listed so readers can set them against the research doses above.

• Body composition and lean mass. The most common community protocol is Mod GRF 1-29 at about 100 mcg plus ipamorelin at 100-300 mcg by subcutaneous injection, often once at bedtime, with some users adding doses after training or on waking. Most describe an empty stomach around each dose. No study has tested that timing for these compounds.
• A specific, slow-healing injury. Users commonly report BPC-157 at 250-500 mcg per day, often injected near the injury, though the animal studies mostly used systemic routes and no human trial has compared injection sites. Vendor guidance for TB-500 describes 2-2.5 mg twice weekly for 4-6 weeks, then monthly maintenance. Forum users describe a wider spread, from 2-5 mg twice weekly to 0.5-2 mg daily or every other day.
• Combined protocols. Some lifters in long training blocks run a GH stack and BPC-157 at the same time. We found no data on the combination, for benefit or for harm.

For on/off schedules and what's known about desensitization, see our page on peptide cycling protocols.

How these protocols compare with steroids and SARMs

Steroids act on the androgen receptor in muscle and most other tissues, and their effect has been measured in people: in a 1996 controlled trial, high-dose testosterone increased muscle size and strength in healthy men. The GH stacks above work upstream by raising the body's own GH and IGF-1, and their human data stop at hormone levels. Our peptides vs. steroids comparison covers that gap in more depth.

For tested athletes the comparison is mostly moot. As of October 2026, WADA's 2026 Prohibited List bans every compound on this page at all times, along with steroids and SARMs (S1). Our guide to how prohibited lists treat peptides explains what that means in practice.

What we still don't know

• Whether any GH stack changes muscle or fat in healthy lifters. The human studies stop at GH and IGF-1.
• Whether the raised GH floor from CJC-1295 with DAC causes more side effects than short-acting stacks over months of use. We found no long-term human data for the DAC form.
• Whether BPC-157 helps human tendons heal. As of October 2026, a University of Arkansas Phase 1 study after rotator cuff repair (NCT07803250, about 30 participants) is listed as not yet recruiting, with a planned start in January 2027.
• Whether BPC-157 plus TB-500 does anything either compound doesn't do alone.